Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.81), $0.15 worse than the analyst estimate of ($1.66). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $13.34 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.